Kintor Pharmaceuticals
Suzhou
China
About Kintor Pharmaceuticals
Suzhou Kintor Pharma is a pharmaceutical company in China.
YEAR FOUNDED:
2009
55 articles about Kintor Pharmaceuticals
-
Inclusion of Kintor as a Constituent Stock of HSCI
8/23/2021
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the company's stock has been included in the Hang Seng Composite Index, effective September 6, 2021.
-
Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China
7/28/2021
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the company has dosed the first batch of subjects in its phase I clinical trial of GT20029 in China.
-
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
7/16/2021
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that Paraguay's Ministry of Public Health and Social Welfare has granted an emergency use authorization for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.
-
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne
7/14/2021
Kintor Pharmaceutical Limited today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug GT20029 for treating androgenetic alopecia (AGA) and acne subjects.
-
Kintor Pharmaceuticals Announces Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S.
4/25/2021
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the phase III clinical trial of proxalutamide for the treatment of male patients with mild or moderate COVID-19 symptoms in the United States has completed the first patient enrollment and dosing.
-
Kintor Pharmaceuticals Announced Successful Dosing of the First Batch of Patients for Acne Vulgaris Phase I/II Clinical Trial of Pyrilutamide
4/16/2021
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first batch of patients enrolment and successfully dosed in China.
-
Kintor Pharmaceutical and Visum Announced Strategic Partnership to Expand Proxalutamide Manufacturing
4/14/2021
Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, recently announced a strategic partnership with Hainan Visum Pharmaceutical Limited ("Visum") to expand proxalutamide manufacturing.
-
Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients
3/11/2021
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalutamide relative to standard of care as assessed by the COVID-19 ordinal scale.
-
Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA
2/2/2021
Kintor Pharmaceutical Limited is pleased to announce that the investigational new drug application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration of China.
-
Clinical Trial of Proxalutamide's Trial of Hospitalized Covid-19 Patients Was Approved in Brazil
1/28/2021
Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the clinical trial (the "Trial") of Proxalutamide's treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board ("IRB") of Brazil .
-
Kintor's Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients
1/10/2021
Kintor Pharmaceutical Limited is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients.
-
Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%
12/10/2020
On December 9, 2020, Kintor Pharmaceutical Limited is pleased to announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 antibody and PD-1 antibody for the second line therapy of advanced hepatocellular carcinoma in Taiwan.
-
Kintor Pharmaceutical's COVID-19 Clinical Trials for Proxalutamide to expand Patient Enrolment
10/29/2020
Kintor Pharmaceutical Limited (Kintor Pharmaceutical, stock code 9939.HK) is delighted to announced that the clinical trial (ClinicalTrials.gov identifier: NCT04446429, registered by Dr. Andy Goren and Applied Biology ) of its anti-androgen treatment Proxalutamide (GT0918) for the novel coronavirus disease (COVID-19) has reac
-
Predicine and Kintor Pharmaceuticals Collaborate on Precision Oncology Clinical Trials and Companion Diagnostics Development
7/3/2018
Predicine, a precision medicine company based in Silicon Valley, announced today that the company has entered into a global strategic partnership with Suzhou Kintor Pharmaceuticals to increase the speed and efficiency of biomarker-driven global clinical trials for Kintor’s novel oncology drugs and the development of companion diagnostics for FDA and CFDA approvals.
-
Suzhou Kintor Raises $44M for Novel Drug Portfolio
1/15/2018
Suzhou Kintor Pharma raised $44M in a funding led by Shenzhen Green Pine Capital Partners.